PT Jayamas Medica Industri (OMED) Fundamentals 2026 — P/E 14.3x, Revenue Analysis | SniperIQ
PT Jayamas Medica Industri (OMED) is a ID-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of Rp5.62T, trading at Rp208.00 on the JKT. This SniperIQ fundamentals page covers PT Jayamas Medica Industri's valuation (P/E 14.3x, P/B 2.0x), profitability (net margin 17.8%), revenue (Rp2.06T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Jayamas Medica Industri's market cap?
PT Jayamas Medica Industri (OMED) has a market capitalization of approximately Rp5.62T, trading at Rp208.00 on the JKT. Market cap moves with the live share price.
What is PT Jayamas Medica Industri's P/E ratio?
PT Jayamas Medica Industri's trailing twelve-month P/E ratio is 14.3x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Jayamas Medica Industri?
PT Jayamas Medica Industri runs a net profit margin of 17.8%, a gross margin of 34.5%, and an operating margin of 19.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Jayamas Medica Industri generate?
PT Jayamas Medica Industri reported revenue of Rp2.06T for fiscal year 2025, with net income of Rp366.9B and earnings per share (EPS) of 13.57. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Jayamas Medica Industri pay a dividend?
PT Jayamas Medica Industri offers a trailing dividend yield of about 2.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is PT Jayamas Medica Industri financially healthy?
PT Jayamas Medica Industri carries a debt-to-equity ratio of 0.09x and a current ratio of 11.08x, with a market beta of 0.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Jayamas Medica Industri a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Jayamas Medica Industri (OMED) the key facts are: market cap Rp5.62T, P/E 14.3x, revenue Rp2.06T, 52-week range 170-318. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Jayamas Medica Industri's full fundamentals live
Get PT Jayamas Medica Industri's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.